Attorney Docket No. 5146

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rudolph, *et al.*

Serial No.: 10/719,485

Filed: 11/21/2003

For: Anilinopyrazole Derivatives Useful for the Treatment of Diabetes

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No.: 48,972

Telephone: (203) 812-6450

Date: DEC 17 2004

Susan M. Pellegrino
Attorney for Applicant(s)
Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Serial No. 10/719,485	Art Unit 1614	Filing Date 11/21/03	Atty. Docket No. 5146
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION		Applicant(s) Rudolph, et al.			

U.S. PATENT DOCUMENTS

*		DOCUMENT NO.							DATE (MM/DD/YY)	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	U5	3	7	9	0	5	7	6	02/05/74				
	U6	3	2	5	7	4	1	0	06/21/66				

FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.							DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB-CLASS	TRANSLATION	
													YES	NO
	F5	9	9	6	4	4	0	7	16/12/99	WO				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.